Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04301765 · ClinicalTrials.gov registry record · Phase 2
Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency
A Phase 2 study of Cancer and Fatigue, sponsored by Seattle Institute for Biomedical and Clinical Research.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 230
- Enrollment target
- 3
- Study locations
NCT04301765 is a Phase 2 study of Cancer and Fatigue that is actively recruiting participants, run by Seattle Institute for Biomedical and Clinical Research. The registered enrollment target is 230 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (93% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT04301765, a Phase 2 study of Cancer and Fatigue, is actively recruiting participants, sponsored by Seattle Institute for Biomedical and Clinical Research.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 230 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a large randomized, double-blind, placebo-controlled trial to determine the efficacy of testosterone replacement on cancer-related fatigue in older men with solid or hematologic (blood) cancer who report fatigue and have low testosterone levels.
Conditions Studied
Interventions
- DRUG testosterone 1.62% gel
- OTHER placebo gel
Study Locations (3)
Georgia
- Georgia Cancer Center at Augusta University - Augusta
Massachusetts
- Brigham and Women's Hospital - Boston
Washington
- Veterans Affairs Puget Sound Health Care System - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2021-01-12 |
| Est. Completion | 2026-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04301765
The ClinicalTrials.gov registry entry for NCT04301765 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 230 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (93% lower). The listed sponsor is Seattle Institute for Biomedical and Clinical Research, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which testosterone 1.62% gel is the first listed.
NCT04301765 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Georgia, Massachusetts, Washington.
Frequently Asked Questions
What is clinical trial NCT04301765 about?
NCT04301765 is a clinical study titled "Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency". This is a large randomized, double-blind, placebo-controlled trial to determine the efficacy of testosterone replacement on cancer-related fatigue in older men with solid or hematologic (blood) cancer who report fatigue and have low testosterone levels.
What is the current status of trial NCT04301765?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 230 participants. The study started on 2021-01-12. Estimated completion is 2026-01-31.
What conditions does trial NCT04301765 study?
This clinical trial studies the following conditions: Cancer, Fatigue, Hypogonadism, Male.
What interventions are being tested in trial NCT04301765?
The interventions under investigation include: testosterone 1.62% gel (DRUG), placebo gel (OTHER).
Who is sponsoring clinical trial NCT04301765?
This trial is sponsored by Seattle Institute for Biomedical and Clinical Research, which has 43 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04301765 being conducted?
This trial has 3 study locations across Georgia, Massachusetts, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
RECRUITING · Phase 2
-
CAncer TReatment INformed by the Molecular Tumor Board At Dartmouth
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Acupuncture for People Experiencing Period Loss Due to Chemotherapy
RECRUITING · Phase 2
-
UCSD Image-Guided Cognitive-Sparing Radiosurgery for Brain Metastases
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.